Health & Biotech
“Market is going to be surprised” as Firebrick Pharma set to launch antiviral nasal spray, Nasodine
Health & Biotech
ASX Health Stocks: EMvision calls its AI brain scanner ’emu’
Health & Biotech
ScoPo’s Powerplays: ASX health stocks flat as a pancake but hopes still of Christmas rally
Health & Biotech
ASX Health Stocks: Rhythm Bio says new research in lung cancer is warranted after this finding
Health & Biotech
ASX Health Stocks: Chimeric jumps 35pc as cell therapy drug shows pre-clinical efficacy
Health & Biotech
Evolt 360 flexes muscles with transformative partnerships in global fitness arena
Health & Biotech
Weed Week: Massive study links cannabis to genetics and schizophrenia, and the best ASX weed stocks right now
Health & Biotech
‘Strongly positioned to move the business forward’: Race Oncology appoints new CEO
Tech
Alta Global acquires longest running MMA community platform ‘The Underground’
Health & Biotech
ASX Health Stocks: Mesoblast partners up for pivotal trial, Alterity in $4.8 million cap raise
Health & Biotech
Why this ASX biotech is primed to capitalise as big pharma flocks to the rare diseases market
Health & Biotech
Allegra’s game-changing Spinal Cage device awaits FDA nod, as ASX medical device stocks make inroads
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.